BioVaxys sabeivirus disease interim data results announced

BioVaxys Technology Corp.
(CSE:BIOV)(FRA:5LB)(OTCQB:BVAXF)("BioVaxys" or the "Company") is pleased to announce that the interim results of its ongoing BVX-1021 preclinical study have shown excellent tolerability with no side effects or notable clinical observations
。 BVX-1021 is a strain developed by the Company for SARS-CoV-1 ("SARS1") and is currently evaluating this vaccine in collaboration with Ohio State University to develop the pansabeivirus vaccine
.

BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys to evaluate the company's novel approach
to treating "universal vaccines" for various Sabeia viruses.
Sabevirus is a family of viruses, including all variants of the new coronavirus, SARS-CoV-1 virus that caused the 2003 global SARS outbreak, and various other potentially dangerous zoonotic viruses
。 The collaboration is evaluating the combination of BioVaxys BVX-0320 and BVX-1021 in guinea pig models; BVX-1021 is a hapten-modified recombinant spike protein S1 subtype from SARS1 virus, while BVX-0320 is a hapten-modified recombinant spike protein S1 subtype
from SARS-CoV-2 ("SARS2").

In a guinea pig animal model BVX-1021 three weeks after administration, no virulence or weight changes were observed, nor were any injection site reactions
observed.

Dr.
David Berd, Chief Medical Officer of BioVaxys, said: "While preclinical results in animal models may not be replicable in humans, emerging tolerability and non-toxic characteristics make clinical evaluation results promising
.
"

The next step in this research is to immunize the test animals with the company's new coronavirus candidate BVX-0320
.
BVX-0320 is a research project
currently underway at The Ohio State University.
The primary endpoint of this study is the development of viral neutralizing antibodies
against the active virus SARS2 and other Sabeia viruses, including SARS-associated coronaviruses in bats and pangolins.
The presence of neutralizing antibodies in animal models strongly suggests that BVX-1021 will increase the immune response
against all Sabey viruses in fully vaccinated and naturally immune populations.

Kenneth Kovan, President and COO of BioVaxys, said, "These interim data further support our efforts
to develop safe and well-tolerated solutions for sabeiviruses such as SARS-1, SARS-CoV-2 and their emerging variants.
The emerging in vivo safety and tolerability profile of BVX-1021 reflects the SARS-CoV-2 epidemic manifestation of BVX-0320 and further demonstrates the feasibility of
the hapten vaccine platform in different viruses.
"